Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA lessened its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 4.0% during the second quarter, Holdings Channel.com reports. The firm owned 91,700 shares of the biotechnology company’s stock after selling 3,800 shares during the quarter. Primecap Management Co. CA’s holdings in Axon Enterprise were worth $26,982,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. 9258 Wealth Management LLC purchased a new stake in shares of Axon Enterprise during the 4th quarter worth approximately $204,000. Principal Securities Inc. purchased a new stake in Axon Enterprise during the 4th quarter worth $49,000. Beacon Pointe Advisors LLC purchased a new stake in Axon Enterprise during the 4th quarter worth $218,000. Level Four Advisory Services LLC boosted its position in Axon Enterprise by 132.4% during the 4th quarter. Level Four Advisory Services LLC now owns 2,677 shares of the biotechnology company’s stock worth $692,000 after purchasing an additional 1,525 shares during the period. Finally, Robeco Institutional Asset Management B.V. boosted its position in Axon Enterprise by 1,049.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 59,319 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 54,160 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Down 0.8 %

Axon Enterprise stock opened at $382.57 on Wednesday. The company has a 50 day moving average price of $340.58 and a 200 day moving average price of $315.24. Axon Enterprise, Inc. has a 52 week low of $189.12 and a 52 week high of $386.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The firm has a market capitalization of $28.87 billion, a price-to-earnings ratio of 111.86, a P/E/G ratio of 10.30 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. During the same quarter in the prior year, the firm earned $0.80 EPS. The company’s revenue was up 34.5% compared to the same quarter last year. Research analysts forecast that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on AXON shares. Craig Hallum upped their price objective on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Robert W. Baird raised their price target on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Bank of America started coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. JMP Securities raised their price objective on shares of Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $400.00 price objective on shares of Axon Enterprise in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $365.38.

Insiders Place Their Bets

In other news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $380.99, for a total transaction of $380,990.00. Following the transaction, the director now owns 27,259 shares in the company, valued at approximately $10,385,406.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Axon Enterprise news, CFO Brittany Bagley sold 4,338 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $378.95, for a total value of $1,643,885.10. Following the sale, the chief financial officer now directly owns 98,825 shares in the company, valued at approximately $37,449,733.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $380.99, for a total transaction of $380,990.00. Following the sale, the director now owns 27,259 shares in the company, valued at $10,385,406.41. The disclosure for this sale can be found here. Insiders sold a total of 317,981 shares of company stock worth $115,662,734 in the last quarter. 6.10% of the stock is currently owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.